Radiopharm Theranostics Limited (RADX) Financial Statements

Income statement

Metric	2026	2025	2024	2023
Revenue
Total Revenue	2.7M	3.6M	299.2K	292.4K
Cost of Revenue	4.8M	3.6M	—	—
Gross Profit	(2.1M)	39.3K	299.2K	292.4K
Operating Expenses
R&D Expense	—	27.5M	17.6M	13.8M
SG&A Expense	15.9M	16.5M	15.2M	13.0M
General & Admin Expense	—	16.5M	15.2M	13.0M
Selling & Marketing Expense	—	—	—	—
Other Expenses	48.9M	(5.8M)	4.1M	8.0M
Total Operating Expenses	64.7M	38.2M	36.9M	34.8M
Cost and Expenses	69.5M	41.8M	36.9M	34.8M
Operating Income (EBIT)	(66.8M)	(38.2M)	(36.6M)	(34.5M)
Non-Operating
Interest Income	—	888.2K	50.5K	145.0K
Interest Expense	109.9K	65.3K	642.9K	86.1K
Net Interest Income	(109.9K)	333.1K	(592.4K)	58.9K
Other Non-Op Income/Expense	11.2M	(65.3K)	(11.2M)	(65.1K)
Non-Operating Income (excl Interest)	—	3.5M	10.6M	(21.0K)
EBT (Pre-Tax Income)	(55.7M)	(38.2M)	(47.9M)	(34.6M)
Income Tax Expense	(53.2K)	103.3K	96.4K	38.0K
Bottom Line
Net Income	(53.9M)	(38.3M)	(47.9M)	(34.6M)
Earnings from Cont. Ops	(55.6M)	(38.3M)	(47.9M)	(34.6M)
Earnings from Discont. Ops	—	—	—	—
Bottom Line Net Income	(53.9M)	(38.3M)	(47.9M)	(34.6M)
Per Share
Basic EPS	($4.56)	($5.28)	($36.00)	($33.00)
Diluted EPS	($4.56)	($5.28)	($36.00)	($33.00)
Revenue Per Share	$0.23	$0.52	$0.23	$0.29
Shares
Basic Shares Outstanding	11.8M	6.9M	1.3M	1.0M
Diluted Shares Outstanding	11.8M	6.9M	1.3M	1.0M
Profitability Metrics
EBITDA	(66.8M)	(38.2M)	(44.1M)	(31.2M)
D&A	—	7.3K	3.1M	3.3M
EBIT	(66.8M)	(38.2M)	(47.2M)	(34.5M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026